An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Purpose: This study aimed to investigate the effect of Semaglutide on skeletal muscle and its metabolomics. Methods: A total of 18 male C57BL/6 mice were randomly divided into normal control (NC) group, high-fat diet (HFD) group and HFD+Semaglutide group, and were given standard diet, HFD diet, HFD diet plus Semaglutide, respectively. The body weight, gastrocnemius weight, serum lipid, blood glucose and inflammatory index levels of mice in each group were observed and compared, and the morphological and structural changes of gastrocnemius were also analyzed. Meanwhile, gastrocnemius metabolite changes were analyzed by untargeted metabolomics. Results: After Semaglutide treatment, the food intake and body weight of mice were evidently decreased, while the relative gastrocnemius weight ratio were conversely increased. Meanwhile, the levels of TG, CHO, LDL, HDL, TNF-α, IL-6, IL-1β and HOMA-IR were all observed to decrease remarkably after Semaglutide intervention. Histological analysis showed that Semaglutide significantly improved the pathological changes of gastrocnemius, manifested as increased type I/type II muscle fiber ratio, total muscle fiber area, muscle fiber density, sarcomere length, mitochondrial number and mitochondrial area. Furthermore, metabolic changes of gastrocnemius after Semaglutide intervention were analyzed, and 141 kinds of differential metabolites were screened out, mainly embodied in lipids and organic acids, and enriched in 9 metabolic pathways including a variety of amino acids. Conclusion: Semaglutide can significantly reduce the body weight and the accumulation of intramuscular fat, promote muscle protein synthesis, increase the relative proportion of skeletal muscle, and improve muscle function of obese mice, possibly by altering the metabolism of muscle lipids and organic acids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Weight-loss therapies such as those using GLP-1 receptor agonists (RA) have shown to be beneficial for sarcopenic obesity, however the data are mainly produced in preclinical studies and proper specific parameters of sarcopenic obesity assessed before and after the introduction of GLP-1 RA are required (92).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, it has shown therapeutic effects on sarcopenic obesity.5”
From Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The emerging evidence suggests that GLP‐1 RAs increase mitochondrial area, number and morphology (i.e., reduces swelling).”
From The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They reported the high fat diet reduced mitochondrial number and area determined by TEM, which was then reversed following semaglutide treatment together with improvements in morphology, that is, reductions in swelling [36].”
From The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, GLP-1 RAs have recently been shown to improve sarcopenic obesity in obese mice by influencing the skeletal muscle metabolism [140,141,142].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [140]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Obesity Among Adults in the United States, 2005 to 2014
Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016) · JAMA · doi:10.1001/jama.2016.6458 · Cited by 2,803
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 1×
“The LBM is mainly composed of skeletal muscle, and lower skeletal muscle mass can lead to poorer glycemic control because it is the main site of glucose processing.(13) Furthermore, the reduction in muscle mass is synergistically accompanied by the accumulation of fat mass in T2DM, leading to the socalled “SO”.”
BackgroundA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“These mechanisms of action support the clinical development of anti-degradative glucagon-like peptide-1 receptor agonists (GLP-1RA) for the obesity, which was associated with type 2 diabetes mellitus, non-alcoholic fatty liver disease, and cardiovascular disease.(10,11) Although there is evidence that GLP-1RA can redu…”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that inhibits glucagon secretion and can lead to weight loss with prolonged use.(8,9) These mechanisms of action support the clinical development of anti-degradative glucagon-like peptide-1 receptor agonists (GLP-1RA) for the obesity, which was associat…”
BackgroundSkeletal muscle: A brief review of structure and function
Frontera, W. R., & Ochala, J. (2015) · Calcified Tissue International · doi:10.1007/s00223-014-9915-y · Cited by 1,758 · cited 1×
“Mitochondria are the main part of energy generation, and the number of mitochondria can directly affect muscle function.(30) Therefore, Semaglutide was inferred to improve muscle function.”
BackgroundObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418 · cited 1×
“associated with increased risk of disability, frailty, cardiometabolic disease, loss of independence, impaired quality of life, and mortality, thereby placing a heavy burden on individuals, societies, and health-care systems.(5,6) The pathogenesis of”
BackgroundSarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 2×
“and oxidative stress all lead to loss of muscle mass and increase of fat mass.(7) Therefore, an in-depth understanding of the underlying mechanism of SO has innumerable benefits for its accurate diagnosis and effective prevention and treatment.”
BackgroundSarcopenic obesity: A new category of obesity in the elderly
Zamboni, M., Mazzali, G., Fantin, F., Rossi, A., & Di Francesco, V. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.10.002 · Cited by 953 · cited 1×
“In turn, muscle catabolism increased insulin resistance, thus resulting in fat mass gain.(28) Accumulating data suggested that GLP-1RAs have anti-inflammatory and insulin resistance-modifying effects.”
BackgroundSarcopenic Obesity Predicts Instrumental Activities of Daily Living Disability in the Elderly
Baumgartner, R. N., Wayne, S. J., Waters, D. L., Janssen, I., Gallagher, D., & Morley, J. E. (2004) · Obesity Research · doi:10.1038/oby.2004.250 · Cited by 937 · cited 1×
“Epidemiological data implied that SO was a better predictor of physical disability in older adults than sarcopenia or obesity alone.(25) Therefore, maintaining muscle mass during weight loss treatment is particularly important.”
Background
Research works printed but not linked: 2
- Christou, 2019, Obesity, 20, 805
- Kalra, 2021, J Pak Med Assoc, 71, 1503
Cited by
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
“Weight-loss therapies such as those using GLP-1 receptor agonists (RA) have shown to be beneficial for sarcopenic obesity, however the data are mainly produced in preclinical studies and proper specific parameters of sarcopenic obesity assessed before and after the introduction of GLP-1 RA are required (92).”
BackgroundNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In addition to weight loss, semaglutide has been shown to lower the intramuscular accumulation of fat and promote protidosynthesis in these mouse models, increasing both mass and muscle function [140].”
BackgroundStrategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149
Self-citationSarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease
Pοlyzos, S. A., Vachliotis, I. D., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155676 · Cited by 107
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
“Semaglutide demonstrated positive effects on body composition [47] with experimental evidence in obese mice showing body weight reduction and an optimal increase in muscle mass [160].”
Metadata
- Authors
- Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X.
- Affiliations
- Hebei Medical University (CN)
- First Hospital of Shijiazhuang (CN)
- Third Hospital of Hebei Medical University (CN)
- Corresponding author
- Chen, Shuchun
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-10
- Volume
- Volume 16
- Pages
- 3723-3735
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9594960
- OpenAlex
- W4307377238
- Cited by
- 91
- References
- 41
- Citations by year
- 2026: 18 · 2025: 43 · 2024: 20 · 2023: 10
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, sarcopenic obesity, skeletal muscle metabolism, gastrocnemius, high-fat diet, intramuscular fat, muscle fiber composition, mitochondrial density, muscle metabolomics, lipid metabolism, amino acid metabolism, insulin resistance, inflammation, muscle protein synthesis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Semaglutide, Animals, Lipids, Male, Mice, Inbred C57BL, Mice, Obese, Obesity, Muscle, Skeletal, Mice, Sarcopenia, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism. https://app.cochat.ai/papers/10.2147/dddt.s381546
- The paper
- Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X. (2022). An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s381546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.